Intravenous administration of brain-targeted stable nucleic acid lipid particles alleviates Machado-Joseph disease neurological phenotype

Biomaterials

Volumn 82, Issue , 2016, Pages 124-137

  Conceição, Mariana ^a,b   Mendonça, Liliana ^a   Nóbrega, Clévio ^a   Gomes, Célia ^c   Costa, Pedro ^a   Hirai, Hirokazu ^d   Moreira, João Nuno ^a,b   Lima, Maria C ^a   Manjunath, N ^e   Pereira de Almeida, Luís ^a,b  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b UNIVERSITY OF COIMBRA   (Portugal)

^c UNIVERSITY OF COIMBRA   (Portugal)

^d GUNMA UNIVERSITY   (Japan)

^e Texas Tech University Health Sciences Center El Paso   (United States)

Author keywords

Behavioral assessment; Brain targeted SNALPs; Intravenous administration; Nanoparticles; Near infrared imaging; Neurodegeneration; SiRNA delivery

Indexed keywords

DISEASE CONTROL; INFRARED DEVICES; NANOPARTICLES; PARTICLE SIZE; PARTICLE SIZE ANALYSIS; PROTEINS; RNA; THERMOGRAPHY (IMAGING); VIRUSES;

BEHAVIORAL ASSESSMENT; INTRAVENOUS ADMINISTRATION; NEAR-INFRARED IMAGING; NEURODEGENERATION; SIRNA DELIVERY;

NEURODEGENERATIVE DISEASES;

ATAXIN 3; LIPID; NANOPARTICLE; NUCLEIC ACID; RABIES VIRUS GLYCOPROTEIN; SMALL INTERFERING RNA; STABLE NUCLEIC ACID LIPID PARTICLE; UNCLASSIFIED DRUG; VIRUS GLYCOPROTEIN; LIPOSOME;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG FORMULATION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MACHADO JOSEPH DISEASE; MALE; MOUSE; NANOENCAPSULATION; NERVE CELL; NEUROPATHOLOGY; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; PROTEIN TARGETING; ANIMAL; BRAIN; C57BL MOUSE; CHEMISTRY; DRUG EFFECTS; DRUG STABILITY; GENE SILENCING; GENETICS; INTRAVENOUS DRUG ADMINISTRATION; MACHADO-JOSEPH DISEASE; PATHOPHYSIOLOGY; PHENOTYPE; TREATMENT OUTCOME;

ANIMALS; BRAIN; DRUG STABILITY; GENE SILENCING; INJECTIONS, INTRAVENOUS; LIPIDS; LIPOSOMES; MACHADO-JOSEPH DISEASE; MICE; MICE, INBRED C57BL; NUCLEIC ACIDS; PARTICLE SIZE; PHENOTYPE; RNA, SMALL INTERFERING; TREATMENT OUTCOME;

EID: 84956644943     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2015.12.021     Document Type: Article

References (53)

1. Schols L., Bauer P., Schmidt T., Schulte T., Riess O. Autosomal dominant cerebellar ataxias: clinical features, genetics, and pathogenesis. Lancet Neurol. 2004, 3:291-304.
2. Taroni F.D. Stefano. Pathways to motor incoordination: the inherited ataxias. Nat. Rev. Neurosci. 2004, 5:641-655.
3. Kawaguchi Y., Okamoto T., Taniwaki M., Aizawa M., Inoue M., Katayama S., et al. CAG expansions in a novel gene for Machado-Joseph disease at chromosome 14q32.1. Nat. Genet. 1994, 8:221-228.
4. Paulson H.L., Perez M.K., Trottier Y., Trojanowski J.Q., Subramony S.H., Das S.S., et al. Intranuclear inclusions of expanded polyglutamine protein in spinocerebellar ataxia type 3. Neuron 1997, 19:333-344.
5. Sudarsky L., Coutinho P. Machado-Joseph disease. Clin. Neurosci. 1995, 3:17-22.
6. Alves S., Regulier E., Nascimento-Ferreira I., Hassig R., Dufour N., Koeppen A., et al. Striatal and nigral pathology in a lentiviral rat model of Machado-Joseph disease. Hum. Mol. Genet. 2008, 17:2071-2083.
7. Alves S., Nascimento-Ferreira I., Auregan G., Hassig R., Dufour N., Brouillet E., et al. Allele-specific RNA silencing of mutant ataxin-3 mediates neuroprotection in a rat model of Machado-Joseph disease. PLoS One 2008, 3:e3341.
8. Alves S., Nascimento-Ferreira I., Dufour N., Hassig R., Auregan G., Nobrega C., et al. Silencing ataxin-3 mitigates degeneration in a rat model of Machado-Joseph disease: no role for wild-type ataxin-3?. Hum. Mol. Genet. 2010, 19:2380-2394.
9. Nóbrega C., Nascimento-Ferreira I., Onofre I., Albuquerque D., Hirai H., Deglon N., et al. Silencing mutant ataxin-3 rescues motor deficits and neuropathology in Machado-Joseph disease transgenic mice. PLoS One 2013, 8:e52396.
10. Nóbrega C., Nascimento-Ferreira I., Onofre I., Albuquerque D., Deglon N., de Almeida L.P. RNA interference mitigates motor and neuropathological deficits in a cerebellar mouse model of Machado-Joseph disease. PLoS One 2014, 9:e100086.
11. Costa Mdo C., Luna-Cancalon K., Fischer S., Ashraf N.S., Ouyang M., Dharia R.M., et al. Toward RNAi therapy for the polyglutamine disease Machado-Joseph disease. Mol. Ther. 2013, 21:1898-1908.
12. Rodriguez-Lebron E., Costa Mdo C., Luna-Cancalon K., Peron T.M., Fischer S., Boudreau R.L., et al. Silencing mutant ATXN3 expression resolves molecular phenotypes in SCA3 transgenic mice. Mol. Ther. 2013, 21:1909-1918.
13. Morrissey D.V., Lockridge J.A., Shaw L., Blanchard K., Jensen K., Breen W., et al. Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat. Biotechnol. 2005, 23:1002-1007.
14. Zimmermann T.S., Lee A.C., Akinc A., Bramlage B., Bumcrot D., Fedoruk M.N., et al. RNAi-mediated gene silencing in non-human primates. Nature 2006, 441:111-114.
15. Mendonca L.S., Firmino F., Moreira J.N., Pedroso de Lima M.C., Simoes S. Transferrin receptor-targeted liposomes encapsulating anti-BCR-ABL siRNA or asODN for chronic myeloid leukemia treatment. Bioconjugate Chem. 2010, 21:157-168.
16. Costa P.M., Cardoso A.L., Mendonca L.S., Serani A., Custodia C., Conceicao M., et al. Tumor-targeted Chlorotoxin-coupled Nanoparticles for Nucleic Acid Delivery to Glioblastoma Cells: A Promising System for Glioblastoma Treatment. Mol. Ther. - Nucleic Acids 2013, 2:e100.
17. Allen T.M., Hansen C., Martin F., Redemann C., Yau-Young A. Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo. Biochim. Biophys. Acta 1991, 1066:29-36.
18. Kraft J.C., Ho R.J. Interactions of indocyanine green and lipid in enhancing near-infrared fluorescence properties: the basis for near-infrared imaging in vivo. Biochemistry 2014, 53:1275-1283.
19. Mendonca L.S., Moreira J.N., de Lima M.C., Simoes S. Co-encapsulation of anti-BCR-ABL siRNA and imatinib mesylate in transferrin receptor-targeted sterically stabilized liposomes for chronic myeloid leukemia treatment. Biotechnol. Bioeng. 2010, 107:884-893.
20. Kumar P., Wu H., McBride J.L., Jung K.E., Kim M.H., Davidson B.L., et al. Transvascular delivery of small interfering RNA to the central nervous system. Nature 2007, 448:39-43.
21. Pulford B., Reim N., Bell A., Veatch J., Forster G., Bender H., et al. Liposome-siRNA-peptide complexes cross the blood-brain barrier and significantly decrease PrP on neuronal cells and PrP in infected cell cultures. PLoS One 2010, 5:e11085.
22. Alvarez-Erviti L., Seow Y., Yin H., Betts C., Lakhal S., Wood M.J. Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat. Biotechnol. 2011, 29:341-345.
23. Tao Y.H., Han J.F., Dou H.Y. Brain-targeting gene delivery using a rabies virus glycoprotein peptide modulated hollow liposome: bio-behavioral study. J. Mater. Chem. 2012, 22:11808-11815.
24. Zadran S., Akopian G., Zadran H., Walsh J., Baudry M. RVG-mediated calpain2 gene silencing in the brain impairs learning and memory. Neuromolecular Med. 2013, 15:74-81.
25. Gao Y., Wang Z.Y., Zhang J., Zhang Y., Huo H., Wang T., et al. RVG-peptide-linked trimethylated chitosan for delivery of siRNA to the brain. Biomacromolecules 2014, 15:1010-1018.
26. Cooper J.M., Wiklander P.B., Nordin J.Z., Al-Shawi R., Wood M.J., Vithlani M., et al. Systemic exosomal siRNA delivery reduced alpha-synuclein aggregates in brains of transgenic mice. Mov. Disord. 2014, 29:1476-1485.
27. Park T.E., Singh B., Li H., Lee J.Y., Kang S.K., Choi Y.J., et al. Enhanced BBB permeability of osmotically active poly(mannitol-co-PEI) modified with rabies virus glycoprotein via selective stimulation of caveolar endocytosis for RNAi therapeutics in Alzheimer's disease. Biomaterials 2015, 38:61-71.
28. Liu Y., Huang R., Han L., Ke W., Shao K., Ye L., et al. Brain-targeting gene delivery and cellular internalization mechanisms for modified rabies virus glycoprotein RVG29 nanoparticles. Biomaterials 2009, 30:4195-4202.
29. Schnell M.J., McGettigan J.P., Wirblich C., Papaneri A. The cell biology of rabies virus: using stealth to reach the brain. Nat. Rev. Microbiol. 2010, 8:51-61.
30. Gong C., Li X., Xu L., Zhang Y.H. Target delivery of a gene into the brain using the RVG29-oligoarginine peptide. Biomaterials 2012, 33:3456-3463.
31. Torashima T., Koyama C., Iizuka A., Mitsumura K., Takayama K., Yanagi S., et al. Lentivector-mediated rescue from cerebellar ataxia in a mouse model of spinocerebellar ataxia. EMBO Rep. 2008, 9:393-399.
32. de Almeida L.P., Zala D., Aebischer P., Deglon N. Neuroprotective effect of a CNTF-expressing lentiviral vector in the quinolinic acid rat model of Huntington's disease. Neurobiol. Dis. 2001, 8:433-446.
33. Moreira J.N., Ishida T., Gaspar R., Allen T.M. Use of the post-insertion technique to insert peptide ligands into pre-formed stealth liposomes with retention of binding activity and cytotoxicity. Pharm. Res. 2002, 19:265-269.
34. Xiong Q., Wilson W.K., Pang J. The Liebermann-Burchard reaction: sulfonation, desaturation, and rearrangment of cholesterol in acid. Lipids 2007, 42:87-96.
35. Nascimento-Ferreira I., Santos-Ferreira T., Sousa-Ferreira L., Auregan G., Onofre I., Alves S., et al. Overexpression of the autophagic beclin-1 protein clears mutant ataxin-3 and alleviates Machado-Joseph disease. Brain a J. neurol. 2011, 134:1400-1415.
36. Mendonça L.S., Nobrega C., Hirai H., Kaspar B.K., Pereira de Almeida L. Transplantation of cerebellar neural stem cells improves motor coordination and neuropathology in Machado-Joseph disease mice. Brain a J. neurol. 2015, 138:320-335.
37. Wender P.A., Mitchell D.J., Pattabiraman K., Pelkey E.T., Steinman L., Rothbard J.B. The design, synthesis, and evaluation of molecules that enable or enhance cellular uptake: peptoid molecular transporters. Proc. Natl. Acad. Sci. 2000, 97:13003-13008.
38. El-Sayed A., Khalil I.A., Kogure K., Futaki S., Harashima H. Octaarginine- and octalysine-modified nanoparticles have different modes of endosomal escape. J. Biol. Chem. 2008, 283:23450-23461.
39. Biswas S., Deshpande P.P., Perche F., Dodwadkar N.S., Sane S.D., Torchilin V.P. Octa-arginine-modified pegylated liposomal doxorubicin: an effective treatment strategy for non-small cell lung cancer. Cancer Lett. 2013, 335:191-200.
40. Zeller S., Choi C.S., Uchil P.D., Ban H.S., Siefert A., Fahmy T.M., et al. Attachment of cell-binding ligands to arginine-rich cell-penetrating peptides enables cytosolic translocation of complexed siRNA. Chem. Biol. 2015, 22:50-62.
41. Simões A.T., Gonçalves N., Koeppen A., Déglon N., Kügler S., Duarte C.B., et al. Calpastatin-mediated inhibition of calpains in the mouse brain prevents mutant ataxin 3 proteolysis, nuclear localization and aggregation, relieving Machado-Joseph disease. Brain a J. neurol. 2012, 135:2428-2439.
42. Greengard P., Allen P.B., Nairn A.C. Beyond the Dopamine Receptor: the DARPP-32/Protein Phosphatase-1 Cascade. Neuron 1999, 23:435-447.
43. de Almeida L.P., Ross C.A., Zala D., Aebischer P., Deglon N. Lentiviral-mediated delivery of mutant huntingtin in the striatum of rats induces a selective neuropathology modulated by polyglutamine repeat size, huntingtin expression levels, and protein length. J. Neurosci. 2002, 22:3473-3483.
44. Lv H., Zhang S., Wang B., Cui S., Yan J. Toxicity of cationic lipids and cationic polymers in gene delivery. J. Control. Release 2006, 114:100-109.
45. Shim M.S., Kwon Y.J. Efficient and targeted delivery of siRNA in vivo. FEBS J. 2010, 277:4814-4827.
46. Semple S.C., Klimuk S.K., Harasym T.O., Dos Santos N., Ansell S.M., Wong K.F., et al. Efficient encapsulation of antisense oligonucleotides in lipid vesicles using ionizable aminolipids: formation of novel small multilamellar vesicle structures. Biochim. Biophys. Acta (BBA) - Biomembr. 2001, 1510:152-166.
47. Hwang do W., Son S., Jang J., Youn H., Lee S., Lee D., et al. A brain-targeted rabies virus glycoprotein-disulfide linked PEI nanocarrier for delivery of neurogenic microRNA. Biomaterials 2011, 32:4968-4975.
48. Son S., Hwang do W., Singha K., Jeong J.H., Park T.G., Lee D.S., et al. RVG peptide tethered bioreducible polyethylenimine for gene delivery to brain. J. Control. Release 2011, 155:18-25.
49. Lorenzer C., Dirin M., Winkler A.-M., Baumann V., Winkler J. Going beyond the liver: progress and challenges of targeted delivery of siRNA therapeutics. J. Control. Release 2015, 203:1-15.
50. Konno A., Shuvaev A.N., Miyake N., Miyake K., Iizuka A., Matsuura S., et al. Mutant ataxin-3 with an abnormally expanded polyglutamine chain disrupts dendritic development and metabotropic glutamate receptor signaling in mouse cerebellar Purkinje cells. Cerebellum 2014, 13:29-41.
51. Conceição M, Mendonça L, Nóbrega C, Gomes C, Costa P, Hirai H, et al. Safety Profile of the Intravenous Administration of Brain-targeted Stable Nucleic Acid Lipid Particles. Data in Brief. Submitted.
52. DiFiglia M., Sena-Esteves M., Chase K., Sapp E., Pfister E., Sass M., et al. Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits. Proc. Natl. Acad. Sci. 2007, 104:17204-17209.
53. Kordasiewicz H.B., Stanek L.M., Wancewicz E.V., Mazur C., McAlonis M.M., Pytel K.A., et al. Sustained therapeutic reversal of Huntington's disease by transient repression of huntingtin synthesis. Neuron 2012, 74:1031-1044.